New pill targets Hard-to-Treat cancers in early trial
NCT ID NCT05653869
Summary
This early-stage study is testing a new oral medication called APS03118 in adults with advanced solid tumors that have specific genetic changes called RET mutations or fusions. The main goals are to find a safe dose and see how the body processes the drug, while also looking for early signs that it might help control the cancer. It is enrolling 108 participants whose cancer cannot be removed by surgery and has spread or grown locally.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RET-ALTERED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030, China
Conditions
Explore the condition pages connected to this study.